Core Viewpoint - A class action lawsuit has been filed against BellRing Brands, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Denha v. BellRing Brands, Inc., No. 1:26-cv-00575 [2]. - Investors have until March 23, 2026, to request to be appointed to lead the case [2]. Group 2: Company Background - BellRing Brands develops, markets, and sells "convenient nutrition" products, primarily ready-to-drink protein shakes under the Premier Protein brand [3]. - The company previously claimed that sales growth was due to increased consumer demand and various positive factors, while downplaying competitive pressures [3]. Group 3: Stock Performance and Impact - On May 6, 2025, BellRing's CFO indicated that several key retailers had lowered their inventory levels, leading to a projected mid-single-digit headwind for Q3 growth, resulting in a stock price drop of $14.88 per share, or 19% [4]. - Following the Q3 2025 financial results reported on August 4, 2025, which included a narrowed fiscal year outlook, the stock dropped by $17.46 per share, nearly 33%, the next day [5][6].

Core Viewpoint - A class action lawsuit has been filed against CoreWeave, Inc. and its senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - CoreWeave is an AI-focused cloud computing company that operates data centers providing high-performance GPU infrastructure, relying on partners like Core Scientific for development [4]. Allegations of Securities Fraud - The lawsuit claims that CoreWeave misrepresented its ability to meet customer demand and concealed construction delays at its data centers, despite assurances of capitalizing on strong demand and competitive strengths [5]. Stock Performance and Impact - On October 30, 2025, CoreWeave's stock dropped by $8.87 (over 6%) after Core Scientific failed to secure enough shareholder votes for a merger, leading to the termination of the merger agreement [6]. - Following a revenue guidance cut on November 10, 2025, due to delays from a third-party developer, the stock fell by $17.22 (over 16%) [7]. - A report on December 15, 2025, regarding further delays in a major data center project led to an additional drop of $2.85 (over 3%) in stock price [8].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case [3]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Ardent Health securities [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health announced a $43 million decrease in revenue for the quarter and increased its professional liability reserves by $54 million, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

Core Viewpoint - Corcept Therapeutics Incorporated is under investigation for potential violations of federal securities laws following the FDA's denial of approval for its new drug application for relacorilant, which is intended to treat hypertension secondary to hypercortisolism [1][2]. Company Summary - On December 31, 2025, Corcept announced it received a Complete Response Letter (CRL) from the FDA, which denied the approval of relacorilant, citing the need for additional evidence of effectiveness despite acknowledging previous trial results [2]. - The stock price of Corcept fell by $31.42 (44.76%) to open at $38.78 per share on the same day, marking a new 52-week low and reaching levels not seen since September 2024 [3].

Core Viewpoint - Hagens Berman is notifying investors about a pending securities class action against F5, Inc. due to allegations of misleading statements regarding the security of its BIG-IP products, which resulted in significant financial losses for investors [1][2]. Group 1: Allegations and Impact - The lawsuit claims that F5 executives misled the market about the security of its core products, particularly after a sophisticated nation-state threat actor allegedly gained long-term access to F5's systems and exfiltrated sensitive source code [2][9]. - Following the revelation of the security breach in October 2025, F5's market value plummeted by over $2 billion, with stock prices experiencing significant declines [2][4]. - The breach led to a disappointing revenue guidance cut for 2026, which was attributed to the security incident, resulting in a drop of F5 shares by $22.83, or 7%, the day after the announcement [9]. Group 2: Legal Proceedings and Investor Actions - The lead plaintiff deadline for the class action is set for February 17, 2026, covering the class period from October 28, 2024, to October 27, 2025 [4][5]. - Hagens Berman is actively investigating the claims and advising investors who purchased F5 shares during the class period and suffered losses [5][6]. - The firm is also encouraging whistleblowers with non-public information regarding F5 to come forward, as they may be eligible for rewards under the SEC Whistleblower program [6].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. and certain officers for alleged violations of federal securities laws during the Class Period from August 3, 2023, to December 26, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Ultragenyx securities during the specified Class Period [2]. - The Complaint alleges that the defendants made false and misleading statements regarding the effects of setrusumab on patients with Osteogenesis Imperfecta and downplayed the risks associated with the Phase III Orbit study [3]. - It is claimed that Ultragenyx's optimism regarding the Phase III study results was unfounded, as the Phase II results lacked a placebo control group, raising concerns about the validity of the reported reduction in annualized fracture rate [3]. Group 2: Next Steps for Investors - Investors affected by the situation have until April 6, 2026, to request to be appointed as lead plaintiff in the class action [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in the lawsuit [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in similar cases [6].

Core Viewpoint - A class action lawsuit has been filed against SLM Corporation (Sallie Mae) on behalf of investors who acquired its securities during the specified Class Period, alleging misleading information regarding loan delinquencies [1][3]. Group 1: Lawsuit Details - The lawsuit claims that during the Class Period from July 25, 2025, to August 14, 2025, Sallie Mae misled investors about the company's loan delinquencies, stating that rising early-stage delinquencies were typical for the season while praising their loss mitigation strategies [3]. - Following the revelation of the true state of loan delinquencies, Sallie Mae's stock price fell by $2.67 per share, or 8.09%, closing at $30.32 on August 15, 2025 [4]. Group 2: Investor Information - Investors who purchased Sallie Mae securities during the Class Period have until February 17, 2026, to seek appointment as lead plaintiff representatives of the class [2].

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock price drops linked to alleged violations of federal securities laws [1][3]. Company Overview - Fermi Inc. is an energy and AI infrastructure company focused on building large-scale nuclear reactors to support grid-independent data centers for AI workloads [4]. - The company's flagship project is Project Matador, designed to provide dedicated power for AI operations [4]. IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations suggest that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Stock Price Impact - On December 12, 2025, Fermi's stock dropped by $5.16 per share, over 33%, following the announcement that the First Tenant was terminating its agreement [7]. - The stock price fell from $15.25 to $10.09 per share in one day due to this news [7]. Legal Proceedings - Investors have until March 6, 2026, to seek appointment as lead plaintiffs in the case, which is pending in the U.S. District Court for the Southern District of New York [3]. - The lawsuit includes claims of securities fraud under various sections of the Securities Exchange Act and the Securities Act [3].

Core Viewpoint - Hub Group Inc. is under investigation for potential violations of federal securities laws, specifically regarding misrepresentation of transportation costs and accounts payable for the first nine months of 2025 [2][3]. Group 1: Investigation Details - Bleichmar Fonti & Auld LLP is leading the investigation into Hub Group for possible misrepresentation of its financial data [2]. - The investigation focuses on whether Hub Group inaccurately reported its purchased transportation costs and accounts payable [2]. Group 2: Stock Performance - Hub Group announced a delay in the release of its fourth quarter and full year 2025 financial results, along with a restatement of its financial statements for the first three quarters of 2025 due to an error that understated costs [3]. - Following this announcement, Hub Group's stock price dropped over 24% during trading on February 6, 2026 [4].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, significantly below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6]. Legal Proceedings - Investors have until February 9, 2026, to request to be appointed to lead the case, which is currently pending in the U.S. District Court for the Southern District of New York [3]. The case is titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. Investor Information - Investors in Integer are encouraged to seek additional information regarding their legal options and can submit their information to the law firm representing the class action [2][7].